The shares of Clovis Oncology, Inc. (NASDAQ:CLVS) has been pegged with a rating of Neutral by BofA/Merrill in its latest research note that was published on August 13th, 2019. BofA/Merrill wasn’t the only research firm that published a report of Clovis Oncology, Inc., with other equities research analysts also giving their opinion on the stock. Guggenheim advised investors in its research note published on August 2nd, 2019, to Neutral the CLVS stock. The stock had earned Sell rating from Goldman when it published its report on May 29th, 2019. The stock was given Buy rating by H.C. Wainwright in its report released on April 15th, 2019, the day when the price target on the stock was placed at $37. H.C. Wainwright was of a view that CLVS is Buy in its latest report on February 13th, 2019 while giving it a price target of $40. Leerink Partners thinks that CLVS is worth Outperform rating. This was contained in the firm’s report on December 4th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $22.00. The price of the stock the last time has raised by 18.27% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 29.04.
The shares of the company dipped by -2.81% during the trading session on Thursday, reaching a low of $5.85 while ending the day at $5.89. During the trading session, a total of 2.72 million shares were traded which represents a 4.51% incline from the average session volume which is 2.85M shares. CLVS had ended its last session trading at 6.06. Clovis Oncology, Inc. currently has a market cap of $298.92M while its P/E earnings growth sits at 2.51, with a beta of 2.05. CLVS 52-week low price stands at $4.98 while its 52-week high price is $37.27.
The company in its last quarterly report recorded -$2.27 earnings per share which is below the -$1.71 predicted by most analysts. The Clovis Oncology, Inc. generated $32.98 million in revenue during the last quarter, which is slightly lower than the $34.92 million predicted by analysts. In the second quarter last year, the firm recorded -$1.63 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 28.19%. Clovis Oncology, Inc. has the potential to record -7.49 EPS for the current fiscal year, according to equities analysts.
Investment analysts at B. Riley FBR published a research note on November 9th, 2018 where it informed investors and clients that Nordic American Tankers Limited (NYSE:NAT) is now rated as Buy. Their price target on the stock stands at $4.25. Guggenheim also rated NAT as Downgrade on August 2nd, 2019, with its price target of $7 suggesting that NAT could surge by 58.7% from its current share price. Even though the stock has been trading at $1.98/share, analysts expect it to surge higher by -0.51% to reach $4.77/share. It started the day trading at $2.03 and traded between $1.96 and $1.97 throughout the trading session.
A look at its technical shows that NAT’s 50-day SMA is 2.10 while its 200-day SMA stands at 2.23. At the moment, only of Nordic American Tankers Limited shares were sold short. The company’s average trading volume currently stands at 1.02M shares, which means that the short-interest ratio is just 3.87 days. Over the past seven days, the company moved, with its shift of 12.57%. Looking further, the stock has dropped -17.23% over the past 90 days while it lost -17.23% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. BlackRock Fund Advisors bought more NAT shares, increasing its portfolio by +2.44% during the last quarter. This move now sees BlackRock Fund Advisors purchasing 147,473 shares in the last quarter, thus it now holds 6,187,414 shares of NAT, with a total valuation of $12,498,576. Morgan Stanley Smith Barney LLC meanwhile bought more NAT shares in the recently filed quarter, changing its stake to $10,666,747 worth of shares. SSgA Funds Management Inc followed the path by increasing its NAT portfolio by +1.66% in the quarter. This means that SSgA Funds Management Inc bought 43,177 shares in the last quarter and now controls 2,647,465 shares of the NAT stock, with the valuation hitting $5,347,879.
Similarly, Citadel Advisors LLC increased its Nordic American Tankers Limited shares by +38.12% during the recently filed quarter. After buying 396,660 shares in the last quarter, the firm now controls 1,437,242 shares of Nordic American Tankers Limited which are valued at $2,903,229. In the same vein, Northern Trust Investments Inc increased its Nordic American Tankers Limited shares by during the most recent reported quarter. The firm bought 18,144 shares during the quarter which increased its stakes to 1,335,442 shares and is now valued at $2,697,593. Following these latest developments, around 1.90% of Nordic American Tankers Limited stocks are owned by institutional investors and hedge funds.